[Adobe Stock Image]Over the past 12 months, a number of medtech companies at various stages hauled in significant funding rounds to support their innovations.

[Adobe股票图片]在过去的12个月里，许多处于不同阶段的医疗技术公司都投入了大量资金来支持他们的创新。

Technologies that were supported by hundreds of millions of dollars in 2024 included pulsed-field ablation, brain-computer interfaces (BCIs), AI-enabled surgical software and more. In all, the amount of medtech companies receiving more than $100 million in a single round reached double digits this year..

2024年获得数亿美元支持的技术包括脉冲场消融、脑机接口（BCI）、人工智能手术软件等。总的来说，今年单轮获得超过一亿美元的医疗技术公司数量达到了两位数。。

Here are the largest medtech funding rounds of 2024 — all of which equaled or exceeded $100 million — of 2024:

以下是2024年最大的医学技术资助回合，所有这些回合都等于或超过了1亿美元：

Blackrock Neurotech — $200 million

贝莱德神经科技公司，2亿

Tether, a cryptocurrency company, announced in April that it made a $200 million strategic investment in Blackrock Neurotech.

加密货币公司Tether在4月份宣布，它对贝莱德神经科技公司进行了2亿美元的战略投资。

The investment — made through a newly formed venture division called Tether Evo — made Tether the majority stakeholder in Blackrock Neurotech, a maker of neurotechnology including BCIs.

这项投资是通过一个新成立的名为Tether Evo的风险部门进行的，使Tether成为包括BCIs在内的神经技术制造商贝莱德神经科技（Blackrock Neurotech）的主要利益相关者。

Blackrock Neurotech develops the NeuroPort Array neural interfacing system. The system, used in human BCIs since 2004, helped patients regain tactile function, movement of limbs and prosthetics and the ability to control digital devices. They can achieve this despite diagnoses of paralysis and other neurological disorders..

贝莱德神经科技公司开发了神经端口阵列神经接口系统。该系统自2004年开始用于人类BCI，帮助患者恢复触觉功能，四肢和假肢的运动以及控制数字设备的能力。尽管诊断出瘫痪和其他神经系统疾病，他们仍能做到这一点。。

Oura — $200 million

Oura-2亿美元

With significant investment from CGM maker Dexcom, smart ring maker Oura closed out 2024 with a $200 million funding round.

凭借CGM制造商Dexcom的大量投资，智能戒指制造商Oura在2024年以两亿美元的融资结束了这轮融资。

The investment came as part of a new health monitoring partnership that aims to combine Dexcom’s glucose insights with Oura’s health-tracking rings.

这项投资是一项新的健康监测合作伙伴关系的一部分，该合作伙伴关系旨在将Dexcom的葡萄糖见解与Oura的健康跟踪环相结合。

Oura said the financing reflects its momentum in building and leading the smart ring category. It expects the new capital to help expand product offerings, fuel further investment in innovation — including AI — and advance global expansion efforts while enabling the exploration of additional acquisitions to accelerate growth..

Oura表示，这笔融资反映了其在建设和领导智能戒指领域的势头。它预计新资金将有助于扩大产品供应，推动包括人工智能在内的创新投资，推动全球扩张，同时能够探索更多收购以加速增长。。

Kestra Medical — $196 million

凯斯特拉医疗-1.96亿美元

The largest medtech funding rounds also included an oversubscribed funding round in July that added $196 million to Kestra Medical’s coffers, supporting the company’s Assure system.

最大规模的medtech融资回合还包括7月份的一轮超额认购融资，为Kestra Medical的金库增加了1.96亿美元，支持该公司的Assure系统。

Assure, a modern wearable cardioverter defibrillator (WCD) system, received FDA approval in 2021. Kestra designed Assure to provide autonomous detection and defibrillation for ventricular arrhythmias. It can also detect and record other clinically significant arrhythmias that may require clinical intervention.

Assure是一种现代可穿戴式心脏复律除颤器（WCD）系统，于2021年获得FDA批准。凯斯特拉设计Assure为室性心律失常提供自主检测和除颤。它还可以检测和记录可能需要临床干预的其他临床上显着的心律失常。

The company says it designed its offering specifically to meet the underserved needs of female cardiac patients as well..

该公司表示，它专门为满足女性心脏病患者服务不足的需求而设计的产品。。

Assure features four channels of ECG, an advanced algorithm and adaptive patient intelligence. The WCD reduces noise and ensures clear data and insights. It also sends an alert to an emergency medical services (EMS) operator after a defibrillator shock.

Assure具有四通道心电图、先进算法和自适应患者智能。WCD减少了噪音，确保了清晰的数据和见解。除颤器电击后，它还会向紧急医疗服务（EMS）操作员发出警报。

Caresyntax — $180 million

Caresyntax-1.8亿美元

In August, San Francisco-based Caresyntax announced that it raised $180 million through a Series C financing extension and growth debt expansion round.

8月，总部位于旧金山的CareStanx宣布，它通过C轮融资延期和增长债务扩张回合筹集了1.8亿美元。

Caresyntax, a vendor-neutral precision surgery platform developer, aims to transform surgery with a scalable, end-to-end software and AI platform. Caresyntax’s medical-grade, interoperable platform allows for the capture and use of novel data and applications. It helps enhance surgical precision and patient safety..

Caresyntax是一家供应商中立的精密手术平台开发人员，旨在通过可扩展的端到端软件和AI平台改造手术。Caresyntax的医疗级可互操作平台允许捕获和使用新颖的数据和应用程序。它有助于提高手术精度和患者安全。。

The company leverages tech and AI to collect, integrate and analyze unique and comprehensive data. Its platform delivers real-time, long-term clinical decision support that enhances the patient journey. The technology also boosts hospital operational efficiency and drives better patient outcomes and profitability..

该公司利用技术和人工智能来收集、整合和分析独特而全面的数据。其平台提供实时、长期的临床决策支持，从而增强患者的旅程。该技术还提高了医院的运营效率，并推动了更好的患者结果和盈利能力。。

Imperative Care — $150 million

紧急护理-1.5亿美元

Campbell, California-based stroke treatment developer Imperative Care made waves in July when it closed an oversubscribed Series E financing with proceeds totaling up to $150 million.

总部位于加利福尼亚州坎贝尔市的中风治疗开发商强制性护理公司在7月份关闭了超额认购的E系列融资，总收益高达1.5亿美元，引起了轩然大波。

The funds — among the largest medtech funding rounds of the year — support the company’s Zoom reperfusion system for the treatment of ischemic stroke, as well as catheter and stent technologies. Imperative Care has four separate entities under its umbrella: Imperative Care Stroke, Imperative Care Vascular, Kandu Health and Telos Health..

这些资金是今年最大的医学技术资助项目之一，用于支持该公司用于治疗缺血性中风的Zoom再灌注系统，以及导管和支架技术。紧急护理有四个独立的实体：紧急护理中风、紧急护理血管、Kandu Health和Telos Health。。

The Imperative Care Stroke business aims to bring life-saving interventional treatments to patients with ischemic and hemorrhagic stroke. Imperative Care Vascular aims to advance treatments for vascular diseases, such as pulmonary embolism. Kandu Health, a digital health company, aims to change the course of stroke recovery and post-acute care through remote support.

紧急护理中风业务旨在为缺血性和出血性中风患者提供挽救生命的介入治疗。紧急护理血管旨在推进血管疾病（如肺栓塞）的治疗。数字健康公司Kandu Health旨在通过远程支持改变中风恢复和急性后护理的过程。

Telo Health utilizes robotics and automation to optimize vascular intervention..

Telo Health利用机器人技术和自动化优化血管干预。。

Insightec — $150 million

Insightec-1.5亿美元

In June, Insightec raised $150 million to further support its incision-less, ultrasound-based neurosurgery technology.

6月，Insightec筹集了1.5亿美元，进一步支持其基于超声波的无切口神经外科技术。

Haifa, Israel–based Insightec — which has its U.S. headquarters in Miami — develops focused ultrasound technology. Its Exablate Prime platform focuses MRI-guided sound waves to provide tremor treatment to patients with medication-refractory essential tremor and Parkinson’s disease.

总部位于以色列海法的Insightec（总部位于迈阿密）开发聚焦超声波技术。其Exablate Prime平台专注于MRI引导的声波，为药物难治性原发性震颤和帕金森病患者提供震颤治疗。

Focused ultrasound has FDA approval to treat both sides of the body. In 2023, the company received positive coverage for its essential tremor therapy. It also has research for future applications in the neuroscience space.

聚焦超声波已获得FDA批准用于治疗身体两侧。2023年，该公司的基本震颤治疗获得了积极的报道。它还对神经科学领域的未来应用进行了研究。

Impulse Dynamics — $136 million

脉冲动力学-1.36亿美元

Heart failure therapy company Impulse Dynamics got a boost in February with a $136 million funding round, which placed it among the largest medtech funding rounds of 2024.

心力衰竭治疗公司Impulse Dynamics在2月份获得了1.36亿美元的资助，这使其成为2024年最大的医疗技术资助回合之一。

Marlton, New Jersey–based Impulse Dynamics said the funds would support, among other things, its INTEGRA-D and AIM HIGHer trials. The company develops the Optimizer Smart Mini system to deliver cardiac contractility modulation (CCM) therapy to the heart. It significantly improves heart contraction to allow more oxygen-rich blood to push out through the body..

。该公司开发了Optimizer Smart Mini系统，为心脏提供心脏收缩力调节（CCM）治疗。它能显著改善心脏收缩，使更多富氧血液通过身体排出。。

INTEGRA-D evaluates the combination of the company’s proprietary CCM therapy with implantable cardioverter defibrillator (ICD) therapy. All this comes through a single device — the Impulse Dynamics Optimizer Integra CCM-D system.

INTEGRA-D评估公司专有CCM治疗与植入式心脏复律除颤器（ICD）治疗的组合。所有这些都来自一个单一的设备-脉冲动力学优化器Integra CCM-D系统。

Mainstay Medical — $125 million

主干医疗-1.25亿美元

In February, Mainstay Medical announced an equity financing worth $125 million set to support the commercial growth of its neurostimulation technology.

2月，Mainstay Medical宣布了价值1.25亿美元的股权融资，以支持其神经刺激技术的商业增长。

ReActiv8, an implantable restorative neuromodulation system, treats adults with intractable chronic low back pain (CLBP) associated with multifidus muscle dysfunction. It holds regulatory approval in Europe, Australia, the UK and U.S. The FDA earlier that month approved the system for MRI labeling as well..

ReActiv8是一种植入式恢复性神经调节系统，用于治疗与多裂肌功能障碍相关的顽固性慢性腰痛（CLBP）。它在欧洲、澳大利亚、英国和美国都获得了监管部门的批准。该月早些时候，FDA也批准了该系统用于MRI标记。。

The company said it wanted to use the funds to support the commercialization of its ReActiv8 system in the U.S., Europe and Australia. It also has eyes on using the money for post-market clinical studies and research, plus general operations.

该公司表示，希望利用这些资金支持其ReActiv8系统在美国、欧洲和澳大利亚的商业化。它还着眼于将资金用于上市后的临床研究和研究，以及一般运营。

Capstan Medical — $110 million

Capstan Medical-1.1亿美元

With a $110 million funding round to close out the year, structural heart surgical robot developer Capstan Medical brought its total funding to more than $150 million.

结构性心脏手术机器人开发商Capstan Medical在今年结束了一轮1.1亿美元的资金投入，使其总资金超过1.5亿美元。

Capstan Medical is developing a surgical robot and catheter-delivered implants for minimally invasive percutaneous replacement of mitral and tricuspid heart valves. The startup hopes to conduct its first-in-human mitral valve procedure by early next year and to follow with the same for its tricuspid valve sometime in 2025..

Capstan Medical正在开发一种外科机器人和导管输送植入物，用于微创经皮置换二尖瓣和三尖瓣心脏瓣膜。这家初创公司希望在明年初进行首次人体二尖瓣手术，并在2025年某个时候对其三尖瓣进行同样的手术。。

The company remains on track to start a pivotal trial of its mitral system in 2026 and submit it for FDA review as soon as 2028.

该公司仍将于2026年开始二尖瓣系统的关键试验，并最快于2028年提交FDA审查。

Magenta Medical — $105 million

品红医疗-1.05亿美元

In July, Magenta Medical closed a $105 million financing round to support Elevate, its miniature heart pump technology. That major round added to $55 million raised in a financing round last year.

7月，品红医疗结束了一轮1.05亿美元的融资，以支持其微型心脏泵技术Elevate。这一主要回合增加了去年融资回合筹集的5500万美元。

Kadima, Israel–based Magenta plans to use the funds to advance its clinical programs for multiple mechanical circulatory support (MCS) indications. It hopes to secure the first FDA approval for Elevate in patients undergoing high-risk percutaneous coronary interventions (HR-PCI).

。它希望确保FDA首次批准接受高危经皮冠状动脉介入治疗（HR-PCI）的患者接受ELEVAT治疗。

Magenta’s high-flow, low-profile device holds a duo of FDA breakthrough device designations. The agency deemed it a breakthrough option for high-risk percutaneous coronary intervention and cardiogenic shock. Magenta completed a first-in-human study in Tbilisi, Georgia, and presented results in 2022.

品红色的高流量、低轮廓设备拥有FDA突破性的两个设备名称。该机构认为它是高危经皮冠状动脉介入治疗和心源性休克的突破性选择。Magenta在格鲁吉亚第比利斯完成了首次人体研究，并于2022年提交了结果。

In August 2023, it completed enrollment in an early feasibility study for the pump. Now, the company plans to launch a pivotal study in the U.S..

2023年8月，它完成了该泵早期可行性研究的注册。。。

Kardium — $104 million

Kardium-1.04亿美元

PFA technology developer Kardium said in June that it raised $104 million to support its Globe system.

PFA技术开发商Kardium在6月份表示，它筹集了1.04亿美元来支持其全球系统。

The new financing enabled Kardium to complete the PULSAR clinical study of its Globe system. Vancouver, British Columbia-based Kardium wants to use the results to obtain regulatory approvals. Funds could also go toward growing the company’s manufacturing team and capacity, as well as building clinical and commercial support in preparation for a commercial launch for Globe..

新的融资使Kardium能够完成其全球系统的脉冲星临床研究。总部位于不列颠哥伦比亚省温哥华的Kardium希望利用这些结果获得监管部门的批准。资金还可以用于增加公司的制造团队和能力，以及建立临床和商业支持，为Globe的商业发布做准备。。

Kardium’s Globe mapping and ablation system features a catheter with a 122-electrode array and advanced software. The platform enables rapid pulmonary vein isolation, high-definition mapping and the ability to ablate anywhere in the atrium. All of these capabilities combine in one single catheter.

Kardium的全球测绘和消融系统具有一个带有122个电极阵列和先进软件的导管。该平台可实现快速肺静脉隔离，高清绘图以及消融心房任何地方的能力。所有这些功能结合在一个导管中。

HistoSonics — $102 million

组织超声学-1.02亿美元

Minnesota-based HistoSonics, developer of a histotripsy treatment for liver tumor procedures, brought in an oversubscribed Series D funding round worth $102 million in August.

总部位于明尼苏达州的HistoSonics是肝肿瘤手术组织学治疗的开发人员，8月份获得了一轮超额认购的D系列资金，价值1.02亿美元。

Edison, HistoSonics’ image-guided therapy system, uses advanced imaging and proprietary sensing technology. It delivers non-invasive, personalized treatments with precision and control. Histotripsy, a novel form of focused ultrasound, uses high-amplitude, very short pulses to create a “bubble cloud.” That cloud mechanically destroys and liquefies targeted liver tumors.

爱迪生，HistoSonics的图像引导治疗系统，使用先进的成像和专有传感技术。它提供精确和可控的非侵入性个性化治疗。。

Histotripsy could offer an alternative to treatments like surgery, radiation and chemotherapy..

组织学检查可以替代手术、放疗和化疗等治疗方法。。

The system received an FDA investigational device exemption in February 2023. A month later, HistoSonics announced the first kidney tumor treatment with its novel therapy system. In October 2023, the FDA granted de novo authorization for the Edison system.

该系统于2023年2月获得FDA研究设备豁免。一个月后，HistoSonics宣布使用其新型治疗系统进行首次肾脏肿瘤治疗。2023年10月，美国食品和药物管理局批准了爱迪生系统的从头授权。

Precision Neuroscience — $102 million

精密神经科学-1.02亿美元

BCI maker Precision Neuroscience announced this month that it closed a Series C funding round worth $102 million. The company says its round makes it one of the best-funded companies in the growing BCI industry.

BCI制造商Precision Neuroscience本月宣布，它完成了一轮价值1.02亿美元的C系列融资。该公司表示，这一轮融资使其成为不断增长的BCI行业中资金最雄厚的公司之一。

Precision Neuroscience plans to use the funds to expand its team, advance its clinical research efforts and refine future versions of its AI-powered brain implant. The company’s Layer 7 thin-film BCI features 1,024 electrodes embedded in a flexible film that conforms to the brain surface. The film comes in at one-fifth the thickness of a human hair..

精密神经科学计划利用这些资金扩大团队规模，推进临床研究工作，改进人工智能大脑植入物的未来版本。该公司的第7层薄膜BCI具有1024个电极，这些电极嵌入到与大脑表面一致的柔性薄膜中。这部电影的厚度只有人类头发的五分之一。。

This device aims to help users with severe paralysis operate digital devices, like computers and smartphones, using their thoughts.

该设备旨在帮助患有严重瘫痪的用户使用他们的想法操作数字设备，如计算机和智能手机。

Amber Therapeutics — $100 million

琥珀疗法-1亿美元

London-based neuromodulation technology developer Amber Therapeutics made a splash with its $100 million Series A round in June, another of the largest medtech funding rounds of 2024.

总部位于伦敦的神经调节技术开发商Amber Therapeutics在6月份以其1亿美元的a轮融资引起了轰动，这是2024年另一轮规模最大的医疗技术融资。

Amber develops adaptive neuromodulation technology to treat mixed urinary incontinence (MUI). Amber-UI, a fully implantable system, targets the pudendal nerve through a novel, minimally invasive surgical procedure. The company labeled it the first fully implantable adaptive neuromodulation therapy in development for women with MUI..

Amber开发了自适应神经调节技术来治疗混合性尿失禁（MUI）。Amber UI是一种完全可植入的系统，通过一种新颖的微创外科手术靶向阴部神经。该公司将其标记为针对患有MUI的女性开发的第一种完全植入式适应性神经调节疗法。。

Amber plans to use the funds raised to support the development of Amber-UI through pilot and pivotal studies. It aims to move toward regulatory approval in the U.S. The company said it already has plans for pilot studies in Europe and a pivotal trial in the U.S. underway.

Amber计划通过试点和关键研究，利用筹集的资金支持Amber UI的开发。该公司表示，已计划在欧洲进行试点研究，并正在美国进行关键试验。